Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ganaxolone - Marinus Pharmaceuticals

Drug Profile

Ganaxolone - Marinus Pharmaceuticals

Alternative Names: CCD-1042; Ganaxalone-IV; gnx; ZTALMY

Latest Information Update: 30 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Purdue Pharma
  • Developer Marinus Pharmaceuticals; Purdue Pharma
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Antimigraines; Anxiolytics; Ketones; Neuroprotectants; Pregnanes; Small molecules
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Status epilepticus; Fragile X syndrome; Epilepsy; Early infantile epileptic encephalopathy 2; Infantile spasms; Tuberous sclerosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Early infantile epileptic encephalopathy 2
  • Phase III Status epilepticus; Tuberous sclerosis
  • Phase II Epilepsy; Fragile X syndrome
  • Phase I Lennox-Gastaut syndrome
  • Suspended Major depressive disorder; Postnatal depression
  • No development reported Angelman syndrome
  • Discontinued Infantile spasms; Migraine; Neuropathic pain; Partial epilepsies; Post-traumatic stress disorders

Most Recent Events

  • 11 Aug 2022 Marinus Pharmaceuticals plans a phase II trial for Llennox-Gastaut Syndrome in 2023
  • 11 Aug 2022 Phase-I clinical trials in Lennox-Gastaut syndrome (In volunteers) in USA (PO) prior to August 2022
  • 11 Aug 2022 Marinus Pharmaceuticals anticipates Medicinal Products for Human Use (CHMP) opinion on the MAA for early infantile epileptic encephalopathy 2 by the end of the first quarter of 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top